Tetracyclines, such as minocycline (MINO), are widely used in the treatment of infectious diseases. This combination therapy is expected to provide both antimicrobial and anti-inflammatory effects. Enhanced cytokine modulation by antibiotics may be a key mechanism in the treatment of severe infectious diseases such as JSF.

Here, we reported a doxorubicin (DOX)-Fe complex and RSL3 co-loaded liposomes (DOX-Fe/RSL3@LIPs) for ferroptosis-enhanced chemotherapy on TNBC tumors. The tumor cell ferroptosis was observably enhanced via supplements of the ferrous ions and H2O2, and RSL3-derived GPX4 inhibition to severely destroy the oxidation balance in cells. In this paper, the DOX-Fe/RSL3@LIPs have exerted a synergistic anticancer effect on TNBC by combining ferroptosis and conventional chemotherapy, and made a meaningful exploration of new strategies for TNBC therapy.

These findings establish MCLRP as a dual-purpose predictive-analytical tool that not only enhances drug response forecasting but also uncovers mutation-specific pharmacological vulnerabilities through systems-level pattern recognition.

This study investigated the renoprotective action of linagliptin compared to doxorubicin against thioacetamide (TAA) and diethyl nitrosamine (DEN)-induced renocarcinogenesis in a rat model. These findings demonstrate that linagliptin, especially at 6 mg/kg/day, exhibits significant renoprotective activities through multifarious mechanisms involving antioxidant action and regulation of key molecular pathways. The present study presents evidence for the potential therapeutic application of linagliptin in renal manifestations of renocarcinogenesis.

OS can be accurately predicted in patients with HCC receiving sorafenib by combining certain radiomics features with clinical metadata, centered primarily on baseline characteristics.

Our results demonstrate that UV-synthesized, albumin-based UV-DOX-NPs not only enhance antileukemic efficacy but also modulate the leukemic immunophenotype and overcome multidrug resistance. These results provide a promising platform for a more targeted and safer leukemia therapy.

P3, N=1186, Recruiting, Children's Oncology Group | Trial completion date: Sep 2027 --> Jun 2029 | Trial primary completion date: Sep 2027 --> Jun 2029

P3, N=610, Recruiting, Shenzhen Third People's Hospital | Not yet recruiting --> Recruiting

In our study, a shift in HDL particles subclasses and functionalities correlated with cardiac alterations in cancer patients and mice treated with DOX. Consequently, our data warrant further research to explore whether targeting HDL particles may represent a therapeutic strategy to limit DOX-induced cardiotoxicity in breast cancer patients.

The patient received four cycles of adjuvant etoposide-cisplatin (EP) chemotherapy. We report a case managed with umbilicus-sparing urachectomy and extended partial cystectomy followed by EP chemotherapy, together with a review of nine previously published cases. These findings provide literature-based evidence to guide individualized management and inform future multidisciplinary research.

TUNEL test revealed that the memantine + doxorubicin group demonstrated significantly more tumor cell apoptosis than the mice in other groups (P-value < 0.05), although tumor volume reduction was not significantly greater than that in the doxorubicin group. This study is the first to demonstrate that memantine can enhance the therapeutic efficacy of doxorubicin chemotherapy while also reducing doxorubicin-induced cardiac oxidative stress and inflammation in a breast cancer model.

Then, apoptotic and antiproliferative effects of the extract of the new isolate were evaluated compared to doxorubicin...This is from the rare reports about this specie of genus Lactobacillus with strong anticancer activity against HT 29 cell lines. The best molecular docking results was detected in the secondary metabolite content encoded as 5,10-dideazatetrahydrofolic acid with an affinity of -9.622 kcal/mol and formed 10 hydrogen bonds with the target protein 1JXQ, resulting in the most stable docking.